INFORMATION BY CANCER TYPE

Immuno oncology

Expert Weighs in on Promising New Options for Frontline Kidney Cancer
BY Angelica Welch
David McDermott, M.D. discusses new advances made to treat kidney cancer. 
Kidney Cancer Trial Recommended to Halt
BY Silas Inman
An independent data monitoring committee recommended that the phase 3 ADAPT trial exploring rocapuldencel-T (AGS-003) for the frontline treatment of metastatic renal cell carcinoma (mRCC) be stopped, but Argos Therapeutics explained that they will keep the trial open. 
Combination May Move to the Frontline for Kidney Cancer
A randomized trial showed that the combination of Tecentriq (atezolizumab) and Avastin (bevacizumab) has some promise for the frontline treatment of some patients with RCC.
Keytruda Benefits Rare Melanoma Subtype in Three Trials
BY Lisa Miller
Three recent trials showed that Keytruda had a durable response for patients with a rare subtype of melanoma.
Immunotherapy Data is Encouraging in Kidney Cancer
BY Danielle Bucco
Elizabeth Plimack, M.D., discusses an update on the CheckMate-025 trial, comparing Opdivo to Afinitor in patients with metastatic renal cell carcinoma.
Expert Discusses Keytruda's Future in Lung Cancer
BY Allie Strickler
Roy Herbst, M.D., Ph.D., spoke with CURE about the future of Keytruda, and immunotherapy in general, to treat lung cancer.
Managing Immunotherapy Side Effects in Melanoma: Quick Intervention Is Key
BY Allie Casey
Immunotherapy agents have their own set of side effects, and managing them quickly and efficiently is key.
Lights, Camera, Cancer
BY Jen Sotham
How and why I've chosen to live my cancer in the public eye.
Working at the Speed of Light in Melanoma Advancements
BY Christin Melton, ELST
Growing scientific insights have led to the swift development of treatments for advanced melanoma, leaving doctors to iron out details about their application.
Hanging on for Dear Life: The Evolving Role of Immunotherapy and Targeted Therapy for Lung Cancer
BY Gina Columbus, Beth Fand Incollingo, Tony Hagen and Brielle Urciuoli
The role of immunotherapies and targeted treatments in lung cancer is evolving at breakneck speed.
Special Feature
Share Your Art
Talk about this article with other patients, caregivers, and advocates in the Immuno-oncology CURE discussion group.
Search Cancer Drugs & Terms